Matches in SemOpenAlex for { <https://semopenalex.org/work/W2240392337> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2240392337 endingPage "5056" @default.
- W2240392337 startingPage "5056" @default.
- W2240392337 abstract "5056 Background: 4-HPR is a synthetic retinoid that, in contrast to other retinoids is cytotoxic rather than a differentiation inducer. Induction of tumor cell ceramide and reactive oxygen species have both been implicated in 4-HPR cytotoxicity. 4-HPR inhibited the growth of ovarian cancer cell lines in vitro with 1–10 μmolar concentrations in a dose dependent manner. A recent phase I study achieved higher levels using an intermittent dosing schedule. Methods: We designed a phase II study to evaluate the activity, toxicity profile and pharmacokinetics of 4-HPR in recurrent ovarian cancer. 4-HPR was administered at a dose of 900 mg/m2 po bid for 7 days every 21 days. Patients were required to have bi-dimensionally measurable disease and could have received ≤ 3 prior chemotherapy regimens for recurrent disease. Results: 24 patients have been enrolled; 22 are evaluable for response. Median number of prior chemotherapy regimens is 3 (range: 1–3). Only 5 patients developed grade 3 or 4 toxicity: 1 grade 3 anemia, 1 grade 4 fatigue, 1 grade 3 diarrhea, 1 grade 3 nausea, and 1 with grade 3 vomiting, diarrhea and abdominal pain. There were no treatment related deaths. The median number of cycles was 2 (range 1–35). The median number of 4-HPR cycles was 2 (range 1–35). Pharmacokinetics obtained in 18 patients showed a day 7 mean Cmax of 7.8 ± 4.7 μM (range 0.61 to 14.6 μM). There have been no objective responses; 8 patients (33%) achieved stable disease. The median progression-free survival (PFS) was 1.5 months (95% CI 1.2–4.1) and the median survival was 9.2 months (CI 4.7–13.4). Six patients remained free of progression for more than 6 months (range 6–25); PFS at 6 months is 30% +/- 10%. Conclusions: The encouraging PFS at 6 months suggest 4-HPR may provide clinical benefit to a significant number of patients. 4-HPR was well tolerated and achieved expected plasma levels for the currently employed formulation. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Epimmune Corp.; Pfizer Ortho Biotech" @default.
- W2240392337 created "2016-06-24" @default.
- W2240392337 creator A5001069506 @default.
- W2240392337 creator A5002013432 @default.
- W2240392337 creator A5012123238 @default.
- W2240392337 creator A5033519939 @default.
- W2240392337 creator A5058354009 @default.
- W2240392337 creator A5062167990 @default.
- W2240392337 creator A5067387322 @default.
- W2240392337 creator A5071585351 @default.
- W2240392337 creator A5081260971 @default.
- W2240392337 date "2004-07-15" @default.
- W2240392337 modified "2023-09-26" @default.
- W2240392337 title "Phase II trial of fenretinide (4-HPR) in recurrent ovarian and primary peritoneal carcinoma: A California Cancer Consortium trial" @default.
- W2240392337 doi "https://doi.org/10.1200/jco.2004.22.90140.5056" @default.
- W2240392337 hasPublicationYear "2004" @default.
- W2240392337 type Work @default.
- W2240392337 sameAs 2240392337 @default.
- W2240392337 citedByCount "3" @default.
- W2240392337 countsByYear W22403923372015 @default.
- W2240392337 crossrefType "journal-article" @default.
- W2240392337 hasAuthorship W2240392337A5001069506 @default.
- W2240392337 hasAuthorship W2240392337A5002013432 @default.
- W2240392337 hasAuthorship W2240392337A5012123238 @default.
- W2240392337 hasAuthorship W2240392337A5033519939 @default.
- W2240392337 hasAuthorship W2240392337A5058354009 @default.
- W2240392337 hasAuthorship W2240392337A5062167990 @default.
- W2240392337 hasAuthorship W2240392337A5067387322 @default.
- W2240392337 hasAuthorship W2240392337A5071585351 @default.
- W2240392337 hasAuthorship W2240392337A5081260971 @default.
- W2240392337 hasConcept C112705442 @default.
- W2240392337 hasConcept C121608353 @default.
- W2240392337 hasConcept C126322002 @default.
- W2240392337 hasConcept C141071460 @default.
- W2240392337 hasConcept C143998085 @default.
- W2240392337 hasConcept C2776694085 @default.
- W2240392337 hasConcept C2777063308 @default.
- W2240392337 hasConcept C2778239845 @default.
- W2240392337 hasConcept C2778248108 @default.
- W2240392337 hasConcept C2780427987 @default.
- W2240392337 hasConcept C2780580376 @default.
- W2240392337 hasConcept C2781451048 @default.
- W2240392337 hasConcept C29730261 @default.
- W2240392337 hasConcept C31760486 @default.
- W2240392337 hasConcept C71924100 @default.
- W2240392337 hasConcept C90924648 @default.
- W2240392337 hasConceptScore W2240392337C112705442 @default.
- W2240392337 hasConceptScore W2240392337C121608353 @default.
- W2240392337 hasConceptScore W2240392337C126322002 @default.
- W2240392337 hasConceptScore W2240392337C141071460 @default.
- W2240392337 hasConceptScore W2240392337C143998085 @default.
- W2240392337 hasConceptScore W2240392337C2776694085 @default.
- W2240392337 hasConceptScore W2240392337C2777063308 @default.
- W2240392337 hasConceptScore W2240392337C2778239845 @default.
- W2240392337 hasConceptScore W2240392337C2778248108 @default.
- W2240392337 hasConceptScore W2240392337C2780427987 @default.
- W2240392337 hasConceptScore W2240392337C2780580376 @default.
- W2240392337 hasConceptScore W2240392337C2781451048 @default.
- W2240392337 hasConceptScore W2240392337C29730261 @default.
- W2240392337 hasConceptScore W2240392337C31760486 @default.
- W2240392337 hasConceptScore W2240392337C71924100 @default.
- W2240392337 hasConceptScore W2240392337C90924648 @default.
- W2240392337 hasIssue "14_suppl" @default.
- W2240392337 hasLocation W22403923371 @default.
- W2240392337 hasOpenAccess W2240392337 @default.
- W2240392337 hasPrimaryLocation W22403923371 @default.
- W2240392337 hasRelatedWork W1967715255 @default.
- W2240392337 hasRelatedWork W1975832547 @default.
- W2240392337 hasRelatedWork W2034009362 @default.
- W2240392337 hasRelatedWork W2060767396 @default.
- W2240392337 hasRelatedWork W2072767112 @default.
- W2240392337 hasRelatedWork W2105623825 @default.
- W2240392337 hasRelatedWork W2361230991 @default.
- W2240392337 hasRelatedWork W2406976129 @default.
- W2240392337 hasRelatedWork W2410995755 @default.
- W2240392337 hasRelatedWork W2968124559 @default.
- W2240392337 hasVolume "22" @default.
- W2240392337 isParatext "false" @default.
- W2240392337 isRetracted "false" @default.
- W2240392337 magId "2240392337" @default.
- W2240392337 workType "article" @default.